The effects of haloperidol on motor vigour and movement fusion during sequential reaching

PLoS One. 2025 Jan 31;20(1):e0316894. doi: 10.1371/journal.pone.0316894. eCollection 2025.

Abstract

Reward is a powerful tool to enhance human motor behaviour with previous research showing that during a sequential reaching movement, a monetary incentive leads to increased speed of each movement (motor vigour effect), whilst reward-based performance feedback increases the speed of transition between movements (movement fusion effect). The neurotransmitter dopamine plays a central role in the processing of reward signals and has been implicated to modulate motor vigour and regulate movement fusion. However, in humans, it is unclear if the same dopaminergic mechanism underlies both processes. To address this, we used a complex sequential reaching task in which rewards were based on movement times (MT). Crucially, MTs could be reduced via: 1) enhanced speed of individual movements (motor vigour effect) and/or 2) enhanced speed of transition between movements (movement fusion effect). 95 participants were randomly assigned to a reward or no reward group and were given either 2.5mg of the dopamine antagonist haloperidol or a placebo (control group). An independent decision-making task performed prior to the main experiment suggested that haloperidol was active during the sequential reaching task (positive control). We did not find evidence that haloperidol affected the facilitatory effects of reward on movement fusion. However, we found that haloperidol negated the reward-based effects on motor vigour. Therefore, our results suggest that a D2-antagonist differentially influences reward-based effects on movement vigour and movement fusion, indicating that the dopaminergic mechanisms underlying these two processes may be distinct.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Dopamine Antagonists / pharmacology
  • Female
  • Haloperidol* / pharmacology
  • Humans
  • Male
  • Movement* / drug effects
  • Psychomotor Performance / drug effects
  • Reward*
  • Young Adult

Substances

  • Haloperidol
  • Dopamine Antagonists

Grants and funding

This work supported by the European Research Council. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.